Valeant will pay $4.5 billion to acquire Bausch + Lomb and another $4.2 billion to cover the ophthalmic product company’s debt.
Valeant did not disclose the number of shares it plans to sell.
More Articles on Ophthalmology:
EyeCRO, Calvert Labs Partner to Perform Preclinical Studies of Ophthalmic Drugs
ForSight VISION5 Names John Maroney President, CEO
16 Statistics on Ophthalmologist Burnout
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
